Understanding Tysabri PML: Testing and Evaluation in Georgia

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Targeted Risk Awareness

If you or a loved one is undergoing treatment with Tysabri, understanding the risk of progressive multifocal leukoencephalopathy (PML) is crucial. The medical community has long emphasized the importance of vigilant monitoring and early detection, building on decades of research into immunosuppressive therapies. This page provides a clear overview of the testing and evaluation process for PML in the context of Tysabri use, drawing from published reports and labeling guidelines.

Understanding Tysabri and Its Associated Risks

Tysabri (natalizumab) is a biologic therapy approved for the treatment of relapsing forms of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus. The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most stringent safety alert, due to the association with PML, which "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning underscores the gravity of the risk and the need for careful patient selection and monitoring. The clinical presentation of PML is variable but typically includes progressive neurological deficits such as weakness, visual disturbances, cognitive decline, and coordination problems. Diagnosis relies on imaging findings, typically brain MRI showing multifocal white matter lesions, and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction. Early recognition is critical because the disease can advance rapidly, leading to irreversible disability or death. The FDA-approved prescribing information for Tysabri emphasizes that healthcare professionals should "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and that "TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanism of PML and Risk Factors

The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking the adhesion molecule VLA-4 on lymphocytes, Tysabri prevents immune cells from crossing the blood-brain barrier. This reduces inflammation in the central nervous system, which is beneficial for controlling multiple sclerosis activity, but it also impairs immune surveillance against JC virus. In immunocompromised individuals, JC virus can reactivate and infect oligodendrocytes, leading to demyelination and the clinical syndrome of PML. The FDA-identified risk factors for PML in Tysabri-treated patients include "the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk, and the risk increases with longer treatment duration, especially beyond two years. The adequacy of warnings regarding Tysabri and PML is a central issue in legal considerations for affected patients. The boxed warning is prominently displayed in the prescribing information, and the drug is only available through a restricted distribution program called the TOUCH Prescribing Program. Under this program, patients must be enrolled, read the Medication Guide, understand the risks, and sign a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether healthcare providers adequately communicated the risk to patients, particularly regarding the significance of anti-JCV antibody testing and the cumulative risk over time.

Legal Considerations and Statute of Limitations in Georgia

For patients who developed PML, the timeline between exposure and documented harm is variable. PML can occur after a few months to several years of Tysabri treatment, as noted in the prescribing information for other serious infections (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This latency period can complicate the determination of when the injury occurred for legal purposes. For individuals in Georgia who have been harmed by Tysabri-associated PML, attorney-related considerations include the statute of limitations, which sets a time limit for filing a lawsuit. In Georgia, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or reasonably should have been discovered. For medical malpractice or product liability claims involving Tysabri, the clock may start when the patient or their family becomes aware of the link between the drug and the PML diagnosis. Given the complexity of PML diagnosis and the potential for delayed recognition, consulting with an attorney experienced in pharmaceutical litigation is advisable to assess the specific timeline and preserve legal rights. The statute of limitations can vary based on the facts of each case, including the date of diagnosis and the date when the connection to Tysabri was understood. In summary, Tysabri carries a known risk of PML, a devastating brain infection. The FDA has mandated strong warnings and a restricted distribution program, but affected patients may still face significant harm. For those in Georgia, understanding the statute of limitations and seeking timely legal advice is crucial. The evidence underscores the importance of careful risk-benefit assessment and vigilant monitoring for any neurological changes during Tysabri therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Georgia?

In Georgia, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or reasonably should have been discovered. For Tysabri-associated PML, this may start when the patient or family becomes aware of the link between the drug and the PML diagnosis. It is crucial to consult an attorney promptly to preserve legal rights.

What are the FDA-identified risk factors for PML in Tysabri patients?

The FDA identifies risk factors including the presence of anti-JCV antibodies, duration of therapy (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed - Tysabri Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.